Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Research Scholarships - Master's program

University of Toronto

$27,000.00

Modelling Early Human Placental Villus Development to Elucidate the Cellular Origins of Preeclampsia

FY 2025-26

Summary
Preeclampsia (PE) is a serious hypertensive disorder of pregnancy that develops after mid-gestation and can cause widespread organ damage in the mother. Worldwide, PE accounts for an estimated 50,000–70,000 maternal and >500,000 neonatal deaths annually. Currently, PE is only resolved by preterm delivery, and there are no existing pharmacologic treatments capable of reversing it. To date, the cellular and molecular mechanisms of PE pathogenesis remain poorly understood, thus necessitating research in early placental development where the initiating defects are believed to occur. Recently, the Lye Laboratory at the Sinai Health Lunenfeld-Tanenbaum Research Institute has developed a three-dimensional spheroid model that recapitulates early stages of human placental villus formation using human trophoblast and embryonic stem cells. Utilizing this model, the current project incorporates patient-derived induced pluripotent and trophoblast stem cells reprogrammed from pregnancies affected and unaffected by PE. There are three objectives: (1) characterize differences in growth, differentiation, and viability between normal and PE-derived cells; (2) model early villus formation using these patient-specific stem cells; and (3) test whether pharmacologic modulation of candidate molecular pathways can restore normal trophoblast development in vitro. Conducted within one of Canada’s leading centres for placental and women’s health research, this approach enables direct comparisons of normal and pathological placentation in a controlled and ethically-sustainable setting; it will ultimately provide new insight into the cellular origins of PE, thus generating foundational knowledge to inform future strategies aimed at preventing or treating PE to improve maternal and fetal outcomes.
Program
Master's Award: Canada Graduate Research Scholarships - Master's program
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
572608
Name
Liu Yunting
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Modelling Early Human Placental Villus Development to Elucidate the Cellular Origins of Preeclampsia
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Research Scholarships - Master's program
Keyworddelim
Embryology; Induced Pluripotent Stem Cells; Lineage Differentiation; Organoid Culture; Placenta; Preeclampsia; Pregnancy Complications; Transcriptomics; Trophoblast Stem Cells; Villus
Abstract
Preeclampsia (PE) is a serious hypertensive disorder of pregnancy that develops after mid-gestation and can cause widespread organ damage in the mother. Worldwide, PE accounts for an estimated 50,000–70,000 maternal and >500,000 neonatal deaths annually. Currently, PE is only resolved by preterm delivery, and there are no existing pharmacologic treatments capable of reversing it. To date, the cellular and molecular mechanisms of PE pathogenesis remain poorly understood, thus necessitating research in early placental development where the initiating defects are believed to occur. Recently, the Lye Laboratory at the Sinai Health Lunenfeld-Tanenbaum Research Institute has developed a three-dimensional spheroid model that recapitulates early stages of human placental villus formation using human trophoblast and embryonic stem cells. Utilizing this model, the current project incorporates patient-derived induced pluripotent and trophoblast stem cells reprogrammed from pregnancies affected and unaffected by PE. There are three objectives: (1) characterize differences in growth, differentiation, and viability between normal and PE-derived cells; (2) model early villus formation using these patient-specific stem cells; and (3) test whether pharmacologic modulation of candidate molecular pathways can restore normal trophoblast development in vitro. Conducted within one of Canada’s leading centres for placental and women’s health research, this approach enables direct comparisons of normal and pathological placentation in a controlled and ethically-sustainable setting; it will ultimately provide new insight into the cellular origins of PE, thus generating foundational knowledge to inform future strategies aimed at preventing or treating PE to improve maternal and fetal outcomes.
Competitiondate
202512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Liu, Yunting
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~